Cellromax Science Q1 2026: Revenue & Op Profit Down, Net Profit Up on Tax Refund

Consolidated Q1 2026 revenue: KRW 4.7B (down 17.6% YoY from KRW 5.7B), operating profit KRW 0.35B (down 59.2% from KRW 0.85B)
Separate net profit: KRW 1.23B (up 72.7% from KRW 0.71B), boosted by one-off tax refund of KRW 0.87B from tax appeal
Shareholder returns: 2025 year-end dividend of KRW 50 per share (total KRW 0.56B); Feb 2026 cancellation of 278,324 treasury shares
On Apr 20, 2026, decided a KRW 1B treasury stock acquisition trust contract (Apr 20 – Oct 21, 2026)
Financial structure: Net debt ratio improved to 2.49% (from 7.06% at year-end 2025); cash & equivalents surged to KRW 3.21B (from KRW 0.68B)
Key investment: KRW 12.17B stake in SN Bioscience (measured at FVTOCI)
R&D expenses: KRW 0.26B (5.6% of revenue); member pharmacies: 6,881 (26.9% of 25,593 nationwide)
Consolidated net debt ratio 2.49%, standalone 2.89% – very stable